Stopping Ozempic may be bad for your health

AI Summary

A study reports that people with type 2 diabetes and no established cardiovascular disease who stop GLP-1 treatment face twice the combined risk of heart attack, stroke, or death compared with those who continue treatment. The findings concern medications such as Ozempic and appeared in The Lancet Regional Health—Europe.

In people with type 2 diabetes (T2D) and no established cardiovascular disease (CVD), starting glucagon-like peptide-1 receptor agonist (GLP-1) treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on treatment, according to a study published in The Lancet Regional Health—Europe.